1-[4-[1-[(2,6-Difluorophenyl)Methyl]-5-[(Methyl-(Phenylmethyl)Amino)Methyl]-2,4-Dioxo-3-Phenylthieno[4,5-e]Pyrimidin-6-Yl]Phenyl]-3- Methoxyurea

CAS: 308831-61-0

Ref. 3D-FD103943

Produktinformation

• Name: 1-[4-[1-[(2,6-Difluorophenyl)Methyl]-5-[(Methyl-(Phenylmethyl)Amino)Methyl]-2,4-Dioxo-3-Phenylthieno[4,5-e]Pyrimidin-6-Yl]Phenyl]-3- Methoxyurea
• Synonyme: 1-{4-[5-{[Benzyl(Methyl)Amino]Methyl}-1-(2,6-Difluorobenzyl)-2,4-Dioxo-3-Phenyl-1,2,3,4-Tetrahydrothieno[2,3-D]Pyrimidin-6-Yl]Phenyl}-3-Methoxyurea, 5-(N-Benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)dione, N-[4-[1-[(2,6-Difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxyurea, Sufugolix, Tak-013, Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxy-
• CAS: 308831-61-0

Beschreibung

(3-Methoxy-1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(methyl-(phenylmethyl)amino)methyl]-2,4-dioxo-3-phenylthieno[4,5-e]pyrimidin-6-yl]phenyl]urea) is a potential drug for the treatment of prostate cancer. This agent has been shown to inhibit the growth of prostate cancer cells in vitro and in vivo. It also inhibits insulin resistance in diabetic rats. The mechanism of action for this drug is not yet known, but it may be due to its ability to bind to estrogen receptors and modulate their function. There are currently no other drugs on the market that target these receptors as a therapeutic strategy for prostate cancer.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 667.73 g/mol
• Formel: C₃₆H₃₁F₂N₅O₄S
• Reinheit: Min. 95%